- Circio presented an extensive circVec data package in an oral and a poster presentation at the ASGCT 2026 Annual Meeting
- The warrant program exercise period between 26 May – 9 June offers the opportunity for warrant holders to subscribe for Circio shares at a discount to the VWAP from the warrant pricing period
- CEO Dr. Erik D Wiklund will summarize the ASGCT presentation, provide an overview of the warrant process and planned use of proceeds for the warrant funds received
Oslo, Norway, 22 May 2026 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing novel circular RNA expression technology for gene and cell therapy, invites to a live webcast in Norwegian at 10:00am CET on Thursday 28 May 2026.
In the webcast, CEO Dr. Erik D Wiklund will summarize the recent oral and poster presentations given at the ASGCT Annual Meeting in Boston 11-15 May 2026 where Circio presented an extensive data package showcasing the latest data package on its circVec circular RNA technology platform. The webcast will also include practical information and timelines relating to the warrant program with exercise period from 26 May to 9 June, including the planned use of proceeds for warrant funds received.
The webcast will be held in Norwegian. Questions can be submitted in advance by email to Erik D Wiklund: erik.wiklund@circio.com or directly in the live webcast.
Time: 10:00 CET on Thursday 28 May 2026
Click here to access Teams webcast
Meeting ID: 332 542 909 160 846
Passcode: kH6xK9CP
A recording of the webcast will be made available on the Circio webpage